140 related articles for article (PubMed ID: 36373800)
1. The maraca plot: A novel visualization of hierarchical composite endpoints.
Karpefors M; Lindholm D; Gasparyan SB
Clin Trials; 2023 Feb; 20(1):84-88. PubMed ID: 36373800
[TBL] [Abstract][Full Text] [Related]
2. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
Liao R; Chakladar S; Gamalo M
Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
[TBL] [Abstract][Full Text] [Related]
3. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
[TBL] [Abstract][Full Text] [Related]
6. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
Gasparyan SB; Buenconsejo J; Kowalewski EK; Oscarsson J; Bengtsson OF; Esterline R; Koch GG; Berwanger O; Kosiborod MN
Ther Innov Regul Sci; 2022 Sep; 56(5):785-794. PubMed ID: 35699910
[TBL] [Abstract][Full Text] [Related]
7. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
Bakal JA; Westerhout CM; Armstrong PW
Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
[TBL] [Abstract][Full Text] [Related]
8. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Pocock SJ; Ariti CA; Collier TJ; Wang D
Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
[TBL] [Abstract][Full Text] [Related]
9. The win ratio approach for composite endpoints: practical guidance based on previous experience.
Redfors B; Gregson J; Crowley A; McAndrew T; Ben-Yehuda O; Stone GW; Pocock SJ
Eur Heart J; 2020 Dec; 41(46):4391-4399. PubMed ID: 32901285
[TBL] [Abstract][Full Text] [Related]
10. Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches.
Ozga AK; Rauch G
BMC Med Res Methodol; 2022 Feb; 22(1):38. PubMed ID: 35123397
[TBL] [Abstract][Full Text] [Related]
11. A systematic comparison of recurrent event models for application to composite endpoints.
Ozga AK; Kieser M; Rauch G
BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
[TBL] [Abstract][Full Text] [Related]
12. Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis.
Wu H; Hou Y; Chen Z
J Eval Clin Pract; 2023 Feb; 29(1):211-217. PubMed ID: 35945813
[TBL] [Abstract][Full Text] [Related]
13. Consistency-ensured parametric tests for critical events of composite endpoints.
Huque MF; Alosh M; Guerra M
J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
[TBL] [Abstract][Full Text] [Related]
14. Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics.
Seifu Y; Mt-Isa S; Duke K; Gamalo-Siebers M; Wang W; Dong G; Kolassa J
J Biopharm Stat; 2023 Nov; 33(6):696-707. PubMed ID: 36545791
[TBL] [Abstract][Full Text] [Related]
15. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization.
Peterson RL; Vock DM; Babiker A; Powers JH; Hunsberger S; Angus B; Paez A; Neaton JD;
Contemp Clin Trials Commun; 2019 Sep; 15():100401. PubMed ID: 31312748
[TBL] [Abstract][Full Text] [Related]
16. Statistical methods for composite endpoints.
Hara H; van Klaveren D; Kogame N; Chichareon P; Modolo R; Tomaniak M; Ono M; Kawashima H; Takahashi K; Capodanno D; Onuma Y; Serruys PW
EuroIntervention; 2021 Apr; 16(18):e1484-e1495. PubMed ID: 32338610
[TBL] [Abstract][Full Text] [Related]
17. Selection of composite binary endpoints in clinical trials.
Bofill Roig M; Gómez Melis G
Biom J; 2018 Mar; 60(2):246-261. PubMed ID: 29023990
[TBL] [Abstract][Full Text] [Related]
18. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
Shah SJ; Borlaug BA; Chung ES; Cutlip DE; Debonnaire P; Fail PS; Gao Q; Hasenfuß G; Kahwash R; Kaye DM; Litwin SE; Lurz P; Massaro JM; Mohan RC; Ricciardi MJ; Solomon SD; Sverdlov AL; Swarup V; van Veldhuisen DJ; Winkler S; Leon MB;
Lancet; 2022 Mar; 399(10330):1130-1140. PubMed ID: 35120593
[TBL] [Abstract][Full Text] [Related]
19. Use of win time for ordered composite endpoints in clinical trials.
Troendle JF; Leifer ES; Yang S; Jeffries N; Kim DY; Joo J; O'Connor CM
Stat Med; 2024 May; 43(10):1920-1932. PubMed ID: 38417455
[TBL] [Abstract][Full Text] [Related]
20. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
Huque MF; Alosh M; Bhore R
J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
